If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

Core Viewpoint - Amgen Inc. is facing a potential increase in stock price according to Bernstein's target, but legal challenges may impact its performance and reputation [1][4][5]. Group 1: Stock Performance - Bernstein has set a price target of $335 for Amgen, suggesting a potential increase of about 1.38% from the current stock price of $330.06 [1][6]. - The stock has fluctuated today, with a low of $321.71 and a high of $330.83, reflecting its volatility [2]. - Over the past year, Amgen's stock has reached a high of $346.38 and a low of $261.43, indicating significant market fluctuations [2][6]. Group 2: Market Capitalization and Trading Activity - Amgen's market capitalization is approximately $177.73 billion, underscoring its substantial presence in the pharmaceutical industry [3]. - The trading volume for the day is 971,158 shares on the NASDAQ exchange, indicating active investor interest [3]. Group 3: Legal Challenges - Amgen is facing a lawsuit from Sagebrush Health Services, alleging unlawful termination of discounted drug sales, which could affect over 10,000 patients in Nevada [4]. - This legal issue may impact Amgen's reputation and financial performance, necessitating close monitoring by investors [5][6].

LAS VEGAS--(BUSINESS WIRE)--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush's clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, temporarily prevented it from supplying its clinics with necessary medications from Amgen and other manufacturers. Guru Ch ...

They are unlikely to resort to dividend cuts anytime soon.Broader equities almost always deliver positive returns over the span of a decade. That's been the case for over 100 years, other than a few 10-year periods that were rocked by significant economic instability. Those exceptions aside, it's a pretty good bet that investors who put their money in stocks today will see competitive returns through 2036.Investing in dividend stocks, which can help boost returns through dividend reinvestment, is particular ...

Evotec SE (NASDAQ:EVO) is one of the best debt-free penny stocks to buy right now. On January 8, the company’s Seattle-based subsidiary Just-Evotec Biologics received a new grant from the Gates Foundation. The grant is to be used to enable global access to the company’s biotherapeutics utilizing Evotec Biologics’ molecular design suite. Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? Copyright: nexusplexus / 123RF Stock Photo The Gates Foundation grant is also part of an effo ...

Core Insights - Amgen reported early Phase 2 data indicating that patients were able to maintain weight loss with less frequent dosing, which could serve as a competitive advantage over Eli Lilly and Novo Nordisk [1] Company Summary - Amgen's Phase 2 data suggests a potential differentiation in its weight management treatment by allowing less frequent dosing while still achieving weight maintenance [1]

Summary of Molecular Partners FY Conference Call Company Overview - **Company Name**: Molecular Partners (NasdaqGS:MOLN) - **Focus**: Development of DARPin candidates, particularly in the field of radiotherapy - **Financial Position**: Over $100 million in cash (approximately CHF 93 million) available for investment in R&D [4][30] Key Industry Insights - **Biotech Sector Outlook**: Increased confidence in a turnaround for the biotech sector in 2026, following a challenging period [3] - **Radiotherapy Market**: Positive feedback and renewed interest in radiotherapy, highlighted by the successful IPO of Aktis Oncology [3] Core Product Focus - **Primary Candidate**: MP0712, a DLL3-targeted DARPin, is expected to drive value creation in the upcoming year [4][6] - **Pipeline Overview**: Emphasis on MP0712, with additional focus on MPO 317 and MPO 533, which are also in development [6][11] Product Development and Clinical Trials - **MPO 317**: Initially considered a dead program, it has been revived due to promising phase one data showing immune activation in colorectal carcinoma. A new trial will involve 75 patients across 11 centers in France, with results expected in 2027 [10][11] - **MPO 533**: A multispecific DARPin targeting acute myeloid leukemia (AML), designed to eradicate residual disease clones. The focus will be on low disease burden patients [11][12] Radiotherapy Mechanism - **Mechanism of Action**: MP0712 utilizes a DARPin vector linked to a radioisotope (Lead-212) to target DLL3 in small cell lung cancer. The approach aims to combine the efficacy of T cell engagers with the durability of antibody-drug conjugates (ADCs) [14][16][18] - **Clinical Strategy**: The company plans to initiate a phase one dose escalation trial, starting with a 75-megabecquerel dose, with a fast-to-market strategy for small cell lung cancer [27][30] Safety and Efficacy Considerations - **Safety Profile**: The rapid decay of Lead-212 is expected to result in minimal hematological toxicity, with recovery of blood values anticipated [34][37] - **Patient Experience**: Radiotherapy is expected to offer a better quality of life for patients compared to T cell engagers, which often cause acute side effects [37] Partnerships and Collaborations - **Orano Med Partnership**: A 50/50 partnership focused on the supply of Lead-212, with Orano Med providing a robust supply chain and infrastructure for the isotope [40][43] - **Future Collaborations**: The company is open to exploring partnerships for other isotopes, such as actinium, to enhance treatment options [45][46] Future Directions - **Expansion of Indications**: Beyond small cell lung cancer, there are plans to explore other neuroendocrine tumors with DLL3 expression [47][48] - **Innovative Imaging Techniques**: The use of imaging agents to select patients with DLL3 expression is seen as pivotal for maximizing treatment efficacy [48] Conclusion - **Focus for 2026**: The primary focus will be on MP0712, with expectations for first-in-human results and safety data in the first half of the year, followed by activity data in the second half [30]

Core Insights - Amgen Inc. presented positive findings from the Phase 2 Study of MariTide, an investigational obesity treatment, at the J.P. Morgan Healthcare Conference, indicating strong weight loss maintenance among participants [1][2] Group 1: Study Results - The majority of participants maintained weight loss for an additional 52 weeks on lower doses of MariTide [1] - The second year of treatment was well tolerated, with low incidence of nausea and no new safety signals [2] - MariTide demonstrated up to 20% average weight loss in individuals with obesity without Type 2 diabetes, and up to 17% in those with the condition, significantly outperforming placebo [3] Group 2: Ongoing Research - Amgen is conducting six Phase 3 studies of MariTide across obesity and related conditions, including diabetes, heart disease, and sleep apnea [4] Group 3: Analyst Perspectives - Analysts express that the 52-week data update aligns with previous observations, but there are questions regarding the necessary dose for quarterly maintenance [5] - A differentiated product profile for MariTide compared to existing GLP-1 therapies suggests potential for significant market share and multibillion-dollar peak sales opportunities [6] - Amgen's stock showed a slight increase of 0.46%, reaching $325.80 at the time of publication [6]

U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 ... ...